WADA publishes revised ISTI, ISTUE and TDSSA to come into force 1 January 2023


WADA publishes revised ISTI, ISTUE and TDSSA to come into force 1 January 2023

The World Anti-Doping Agency (WADA) has published the revised International Standard for Testing and Investigations (ISTI), revised International Standard for Therapeutic Use Exemptions (ISTUE) and version 8.0 of the Technical Document for Sport Specific Analysis (TDSSA) all to come into force 1 January 2023. 

The ISTI establishes mandatory standards for the process of testing athletes through sample collection and also mandatory standards for the conduct of investigations into possible Anti-Doping Rule Violations. 

The ISTUE provides the process for applying for and recognising athlete Therapeutic Use Exemptions (TUE’s) which can be granted when an athlete needs to use a substance or method that is specifically included on WADA’s List of Prohibited Substances and Methods due to an ongoing medical condition. 

The TDSSA is intended to ensure that the Prohibited Substances and/or Prohibited Methods within the scope of the TDSSA are subject to an appropriate and consistent minimum level of analysis by all ADOs that conduct testing in those sports or disciplines deemed at risk.

You can read the WADA statement here

You may also like

View All

Tour de France introduces yellow cards to tackle unsportsmanlike conduct

The Tour de France may issue yellow cards for unsportsmanlike behaviour, sparking debate over clarity

Read More

Queensland and federal governments agree on funding deal for the 2032 Games

The Queensland and federal governments have reached an agreement on a funding deal for the 2032 Olympic and Paralympic Games

Read More

WADA publishes stakeholder and athlete feedback from third phase of 2027 Code review

WADA has published its stakeholder feedback from the Third Consultation Phase of the 2027 WADA Code and International Standards Update Process and from the Athlete-Centered Consultation on the same subject

Read More

Newsletter Signup

Please enter your email address below: